hPSC-Derived Venous Endothelial Cells for Hemophilia A Therapy

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Current methods for generating human liver sinusoidal endothelial cells (LSECs) are inefficient and lack understanding of early developmental steps, particularly mesoderm induction, which is crucial for lineage commitment and therapeutic applications in diseases like Hemophilia A and liver disorders.

Innovation Solution

A protocol is developed to generate human pluripotent stem cell (hPSC)-derived venous endothelial cells (VECs) by modulating BMP and Activin signaling to induce mesoderm with a KDR+ CD235a/b+ phenotype, resulting in a population with up to 50-fold greater engraftment potential and efficient differentiation into functional LSECs, using embryoid bodies and monolayer cultures.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Productivity

If conventional methods are used to generate hPSC-derived venous endothelial cells, then the protocol is simpler, but the engraftment efficiency is low and LSEC potential is limited

Engineering Contradiction:

Improveengraftment efficiencyVSAvoidprotocol complexity

Core Design Contradiction:

ProductivityVSDevice complexity

Solution Approach 1:

The protocol performs preliminary mesoderm induction with specific BMP and Activin signaling optimization before endothelial differentiation. This preliminary action creates a KDR+CD235a/b+ mesoderm population that is pre-configured for high engraftment potential, thereby resolving the contradiction by preparing cells in advance with the correct lineage commitment before the actual differentiation step

Inventive Principle:

Principle #10Preliminary action

Solution Approach 2:

The invention changes key parameters of mesoderm induction by optimizing BMP4 and Activin A concentrations and timing. This parameter optimization transforms the differentiation protocol to generate mesoderm with enhanced LSEC potential, achieving up to 50-fold greater engraftment efficiency while maintaining a manageable protocol framework

Inventive Principle:

Principle #35Parameter changes

2Reliability

If mesoderm induction is not optimized, then the protocol is easier to perform, but the understanding of early developmental steps is insufficient and therapeutic efficacy is reduced

Engineering Contradiction:

Improvetherapeutic efficacyVSAvoidprotocol complexity

Core Design Contradiction:

ReliabilityVSDevice complexity

Solution Approach 1:

The protocol incorporates feedback mechanisms by using specific molecular markers (KDR, CD235a/b) to monitor mesoderm induction quality. This feedback system ensures that only mesoderm with the correct phenotype proceeds to differentiation, thereby guaranteeing therapeutic efficacy while providing clear quality control checkpoints in the protocol

Inventive Principle:

Principle #23Feedback

Solution Approach 2:

The invention performs preliminary optimization of mesoderm induction parameters based on understanding of early developmental biology. This preliminary action incorporates developmental insights into the protocol design, ensuring that mesoderm is induced with the correct lineage commitment markers before differentiation, thereby enhancing reliability without excessive complexity

Inventive Principle:

Principle #10Preliminary action

Data Source

PatentUS20230332108A1Endothelial cells and methods of making and using

Publication Date: 2023.10.19 UNIV HEALTH NETWORK

AI summary

This disclosure describes vascular endothelial cells (VECs) and liver sinusoidal endothelial cells (LSECs), and methods and compositions for producing such cells.